首页> 外文期刊>Research on Chemical Intermediates >Design, synthesis of novel quinazolin-4-one derivatives and biological evaluation against human MCF-7 breast cancer cell line
【24h】

Design, synthesis of novel quinazolin-4-one derivatives and biological evaluation against human MCF-7 breast cancer cell line

机译:新型喹唑啉-4-酮衍生物的设计,合成及对人MCF-7乳腺癌细胞的生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

A new series of 6,8-dibromo-2-(4-chlorophenyl)quinazolin-4(3H)-one derivatives VI-XIII were synthesized. Their chemical structures were confirmed by spectral and elemental analysis. The cytotoxic effect of the newly synthesized compounds was tested in vitro against human breast cancer cell line (MCF-7). Most of the tested compounds have shown promising cytotoxic activity. Compounds X and XIIIb exerted a powerful cytotoxic effect against MCF-7 with a very low IC50 (0.0015 and 0.0047 A mu mol/ml), while compounds VI, VII, VIII, XIIb, XI, XIIIc and IX exerted a moderate cytotoxic effect (IC50 0.01523, 0.0213, 0.031, 0.0478, 0.049, 0.068 and 0.079 A mu mol/ml respectively), compared to doxorubicin (0.0025 A mu mol/ml). Exploring their apoptotic effect; interestingly,all compounds activated apoptotic cascade in MCF-7. Compounds VI, XIIIb, XIIb, XI, XIIa, VII, V and VIII showed potent effect even much more than doxorubicin by 12.87-5.91 folds, while compounds XIIIc, IX, XIIIa, XIIc and X showed moderate increase in CASP3 activity by 4.96-3.22 folds relative to untreated cells more or less similar to doxorubicin (5.57 folds).
机译:合成了一系列新的6,8-二溴-2-(4-氯苯基)喹唑啉-4(3H)-一衍生物VI-XIII。通过光谱和元素分析证实了它们的化学结构。在体外测试了新合成化合物对人乳腺癌细胞系(MCF-7)的细胞毒性作用。大多数测试化合物显示出有希望的细胞毒性活性。化合物X和XIIIb对MCF-7表现出强大的细胞毒性作用,IC50极低(0.0015和0.0047 Aμmol / ml),而化合物VI,VII,VIII,XIIb,XI,XIIIc和IX表现出中等的细胞毒性作用(与阿霉素(0.0025 Aμmol / ml)相比,IC50分别为0.01523、0.0213、0.031、0.0478、0.049、0.068和0.079 Aμmol / ml。探索它们的凋亡作用;有趣的是,所有化合物都激活了MCF-7中的凋亡级联反应。化合物VI,XIIIb,XIIb,XI,XIIa,VII,V和VIII的效力比阿霉素高出12.87-5.91倍,而化合物XIIIc,IX,XIIIa,XIIc和X的CASP3活性则适度增加了4.96-相对于未处理的细胞3.22倍或多或少类似于阿霉素(5.57倍)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号